Stay updated on Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page.

Latest updates to the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now displays the clinical trial record, including its study design, eligibility criteria, interventions, outcomes, investigators, and publication details.SummaryDifference46%

- Check20 days agoChange DetectedThe ClinicalTrials.gov footer now lists revision v3.8.0 instead of v3.7.2. The study record remains inaccessible behind a 403 Forbidden page.SummaryDifference0.2%

- Check27 days agoChange DetectedA sitewide NIH notice announces a terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check34 days agoChange DetectedThe site revision label in the footer changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.0 to v3.7.1; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details and navigation with a standard error page; the previously visible study information is no longer accessible on this page.SummaryDifference18%

Stay in the know with updates to Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page.